Introduction
TSAO derivatives are potent and highly specific inhibitors of human immunodeficiency virus type 1 (HIV-1) replication in cell culture (Balzarini et al., 1992a ,bj Camarasa et al., 1992 Perez-Perez et al., 1992) . The prototype compound is [1-[2~,5' -bis-O-(tert-butyldimethylsilyl) -/3-D-ribo-furanosyl]thymine] -3' -spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide), designated TSAO-T (lj Fig. 1 ). They are specifically targeted at a non-substrate binding site of the HIV-1 reverse transcriptase (RT; Balzarini et al., 1992c , 1993aj Camarasa et al., 1995 .
Within this class of compounds, stringent requirements exist with regard to the structural determinants for optimum anti-HIV activity in cell culture. The presence of tert-butyldimethylsilyl (TBDMS) groups at both the C-2' and C-5' positions and of the unique 3'-spiro group [3'spiro-5"-(4"-amino-1",2" -oxathiole-2",21/-dioxide)) in nucleosides with a D-ribo configuration is a prerequisite for antiviral activity (Balzarini et al., 1992bj Camarasa et al., 1992j Perez-Perez et al., 1992 Ingate et al., 1995; Velazquez et al., 1994) . In contrast, the nature of the hete-. rocyclic base is less critical for anti-HIV-1 activity. The thymine moiety ofTSAO-T can be replaced by a number of other pyrimidines, purines and 1,2,3-triazoles without a marked decrease in antiviral efficacy (Camarasa et al., 1992j Perez-Perez et al., 1992j Alvarez et aI., 1994 Velazquez et al., 1993; San-Felix et al., 1994) .
Rapid emergence of TSAO-resistant HIV-1 strains Occurs when HIV-1-infected cells are exposed to TSAO derivatives (Balzarini et al., 1993a (Balzarini et al., ,b,c, 1994 . TSAO compounds consistently select for HIV-1 strains that contain a single amino acid mutation, replacing the glutamic acid at position 138 of the p51 RT subunit by a lysine. These Lys-138 RT-mutated virus strains are highly resistant to the inhibitory effect ofTSAO (Balzarini et al., 1993b . Our experimental data strongly suggest a specific interaction between th'c carboxylate group of GIu-138 of the p51 subunit and the 4"-amino group of the 3'spiro moiety ofTSAO Jonckheere et al., 1994; Boyer et al., 1994) . In addition, other amino acids in the non-nucleoside RT inhibitor-binding pocket, at the level of the p66 RT subunit, have also been found to be crucial for TSAO interaction with RT (Balzarini et al., 1993a) . Thus, well-defined amino acids both in the p51 and p66 RT subunits are needed for an optimum interaction ofTSAO with both subunits at the same time. These observations indicate that among HIV-1-speeific RT inhibitors the TSAO molecules represent a unique class of compounds that are able to interfere at the interface between both RT domains.
As part of our programme to explore further the importance of substituent effects on the anti-HIV-1 activity of TSAO derivatives, we focused our attention on modifications of the 3'-spiro moiety of TSAO compounds. This represents the part of the molecule closest to the interface between the p51 and p66 subunit domains. Novel TSAO analogues were designed in which the spiro amino-oxathioledioxide was replaced by other spiro moieties that maintain an NH 2 group at the 4"-position. This amino group has been proposed to be responsible for the interaction of the prototype compound TSAO-T (1) with the p51 subunit of the enzyme. Moreover, since amino acid residues 136 and 137, adjacent to Glu-138 on the p51 RT subunit, are two asparagine (Asn) residues that are highly conserved in all. HIV-1, HIV-2 and simian immunodeficiency virus strains (Myers et al., 1994) , and since it has been described that Asn strongly interacts with -CONH-functions (Hardy & Nalivaika, 1992; Graves et al., 1992) , compounds 6 and 7, which have a 3'-spiro oxazolone moiety with a -CONH-grouping near the 4"-NH group may also interact with these residues. This additional interaction may enhance the antiretroviral potency and/or may broaden the antiretroviral spectrum of TSAO derivatives. In addition, by interacting with these amino acid positions, resistance development may be delayed or even avoided since these locations have proven to be less prone to mutation than many other parts of the RT gene. In this paper we report the synthesis and anti-HIV activity of novel TSAO analogues modified at the 3'-spiro moiety. The results described here constitute the 508 first examples of 3'-spiro nucleosides bearing a 4"-amino-2"-oxazolone or a 4"-amino-1",2",3"-oxathiazole-2",2"dioxide moiety at the 3'-position of the sugar.
Materials and Experimental Procedures: Chemistry
Microanalyses were obtained with a Heraeus CHN-O-RAPID instrument. IH NMR spectra were recorded with a Varian Gemini, a Varian XL-300 and a Bruker AM-200 spectrometer operating at 300 and 200 MHz and a Varian Unity 500 spectrometer operating at 498.84 MHz with Me 4Si as the internal standard. 13C NMR spectra were recorded with a Bruker AM-200 spectrometer operating at 50 MHz, with Me 4Si as the internal standard. IR spectra were recorded with a Shimadzu IR-435 spectrometer. Analytical TLC was performed on silica gel 60 F 254 (Merck). Separations on silica gel were performed by preparative centrifugal circularTl.C (CCTLC) on a chromatotron (Kiesegel 60 PF 254 gipshaltig; Merck), layer thickness 1 mm, flow rate 5 mL min-I. Flash column chromatography was performed with silica gel 60 (230-400 mesh; Merck). [1] [2] and [1-[2',5'-bis-O-(tert-butyldimethylsilyl) -/3-D-ribofuranosy/Jthymine]-3'spiro-5"-(4"-amino-2"-oxazolone) (6 and 7)
A mixture of the 3'-ketonucleoside 3 (Calvo-Mateo et al., 1988a) (242 mg, 0.5 mmol), water (1 mL), ethyl ether (2 mL), sodium bicarbonate (84 mg, 1 mmol) and sodium cyanide (24.5 mg, 0.5 mmol) was stirred vigorously at room temperature for 16 h. The organic phase was separated and the aqueous phase was washed with ethyl ether (2x2 mL). The combined ethereal phases were dried over anhydrous sodium sulphate, filtered and evaporated to dryness. The residue,a mixture of the two epimeric cyanohydrins 4 and 5, was dissolved in dry methylene cWoride (2 mL). To this solution, chlorosulphonyl isocyanate (5l!L, 0.75 mmol) was added. The mixture was stirred at room temperature fcir 5 h and then methylene chloride (20 mL) and saturated aqueous NaHC0 3 (20 mL) were added. After stirring at room temperature for 1 h the organic phase was separated and the aqueous phase was extracted with methylene chloride (2x 10 mL). The combined organics were washed with brine (20 mL), dried (N~S04)' filtered and the solvent was removed. The residue was purified by CCTLC on the chromatotron (cWoroform:ethanol,30: 1) to give 184 mg (66%) of a 4.5: 1 mixture of spironucleosides 6 and 7 as a white foam. This mixture was chromatographed again on the chromatotron (hexane:ethyl acetate, 1:2). The fastest moving fractions afforded 116 mg of 6 as an amorphous solid. IR (KBr) 3250 crn'", 3050 (NH), 1750, 1720, 1685 (C-4", C=O, C=N), 1645 (C=C-N). Anal. calcd for C24H42NP7Si2: C, 51.96; H, 7.63; N, 10.10. Found: C, 52.29; H, 7.73; N, 10.52 . The slowest moving fractions afforded 68 mg of a mixture (l : 1) of spironucleosides 6 and 7. '-spiro-5"-(4/1-N-methylimino-3 " -N-methyl-2/1-oxazolidinone) (9 and 10) To a solution of8 (200 mg, 0.35 mmol) in acetone (5 mL) Was added~C03 (24 mg, 0.17 mmol) and methyl iodide (21 ilL, 0.34 inmol). The reaction mixture was refluxed for 8 h. The solvent was evaporated to dryness and the residue was dissolved in ethyl acetate (10 mL) and successively washed with water (2 x 10 mL) and brine (10 mL). The organic phase was dried over anhydrous Na 2S04, filtered and evaporated to dryness. The residue was purified by CCTLC on the chromatotron (hexane:ethyl acetate, 2: 1). The fastest moving band gave 61 mg (30%) of 10 as a (Hayakawa et al., 1987) (6 g, 15.61 mmol) in acetone (125 mL), was added K 2C03 (1.08 g, 7.81 rnmol) and methyl iodide (3.9 mL, 62.48 mmol). The reaction mixture was refluxed for 15 h. The solvent was evaporated to dryness. The residue was dissolved in ethyl acetate (150 mL), and successively washed with water (2x 100 mL) and brine (100 mL). The organic phase was dried Over anhydrous Na 2S04, filtered and evaporated to dryness. The residue was purified by column chromatography with hexane: ethyl acetate (1: 1) as the eluent to give 12 (5.2 g, 84%) as a syrup. 1H NMR (CDCI 3, 300 MHz) Antiviral Chemistry & Chemotherapy 8 (6) 3' Spiro nucleoside analogues of TSAo-T fl 1.98 (s, 3H, CH 3-5), 2.11, 2.13, 2.15 (3s, 9H, 3CH 3CO), 3.34 (s, 3H, CH 3-3), 4.34-4.36 (m, 2H, H-5'a, H-5'b), 4.47-4.51 (m, 1H, H-4'), 5.16 (dd, 1H, ;f1-2', J 1',2' 2.8, J 2',3' 1.7 Hz), 5.37 (dd, 1H, H-3', J 3',4' 3.9 Hz), 6.11 (d, 1H, H-1'). Anal. calcd for C17H22N209: C, 51.26; H, 5.57; N, 7.03. Found: C, 51.11; H, 5.39; N, 5 
The protected nucleoside 12 (5 g, 12.56 mrnol) was treated with saturated methanolic ammonia (280 mL). After standing at room temperature overnight, the solvent was evaporated to dryness and the residue was treated with ether (50 mL). The-solid (2',3',5'-O-deprotected nucleoside) was filtered and suspended in dry pyridine (25 mL) and then tert-butyldimethylsilyl chloride (5.68 g, 37.68 mmol) was added. The mixture was stirred at room temperature for 48 h. The solvent was evaporated under reduced pressure and the residue, dissolved in chloroform (100 mL), was successively washed with cold We) 1 M HCI (50 mL), water (100 mL) and brine (100 mL), and finally dried over anhydrous Na 2S04, filtered and evaporated to dryness. The residue was purified by column chromatography using hexane: ethyl acetate (5: 1) as the eluent, to give compound 13 (3,45 g, 55%) as an amorphous solid. , 55.16; H, 8.86; N, 5.59. Found: C, 54.88; H, 8.74; N, 
To a solution ofCr0 3 (1.79 g, 17.97 mmol), pyridine (2.9 mL, 35.94 mmol), acetic anhydride (1.69 mL, 17.97 mmol) and methylene chloride (25 mL) was added compound 13 (3 g, 5.99 mmol). The resulting mixture was stirred at room temperature for 1 h and then evaporated to dryness. The residue was treated with ethyl acetate (15 mL) and filtered through a short silica gel column (20 g) using ethyl acetate as the eluerrt,The filtered solution was evaporated to dryness and the residue coevaporated with ethanol (3x5 mL) to give 14 (2,45 g, 82%) as a white foam. IR (KBr) 1785 cm'", 1715, 1665 (C=O), 1645 (C=C-N). 1H NMR (CDCI 3, 300 MHz) fl 0.84, 0.91 (2s, 18H, 2t-Bu), 1.98 (s, 3H, CH 3-5), 3.36 (s, 3H, CH 3-3), 3.92 (bs, 2H, H-5'a, H-5'b), 4.19 (d, 1H, H-2',J1',2' 8.2 Hz), 4.21 (bs, 1H, H-4'), 6.29 (d, 1H, H-1'), 7,48 (s, 1H, H-6). Anal. calcd for C23H42NP6Si2: C, 55.39; H, 8, 49; N, 5.62. Found: C, 55.14; H, 8, 40; N, 5.83 . [1] [2] '-spiro-5"-(4"-amino-2"-oxazolone) and [1-[2',5'-bis-O-(tert-butyldimethylsilyl) -f3-D-ribofuranosyl]-3-Nmethyl-thymine]-3'-spiro-5"-(4"-amino-2"oxazolone) (8 and 17) Following the procedure described for the synthesis of compounds 6 and 7, the 3'-ketonuc1eoside 14 (1 g, 2 mmol) was treated with NaCN (0.09 g, 2 mmol), NaHC0 3 (0.33 g, 4 mmol) and then with CSI (0.26 mL; 3 mmol) for 5 h. Methylene chloride (20 mL) and saturated aqueous NaHC0 3 (30 mL) were added. After stirring at room temperature for 1 h the organic phase was separated and the aqueousphase was extractedwith methylene chloride (2 x 30 mL). The combined organics were washed with brine (100 mL), dried (Na 2S04), filtered and the solvent was removed. The residue was purified by column chromatographywith hexane: ethyl acetate (3 : 1). The fastest moving fractions afforded 0.49 g (43%) of8 as an amorphous solid. IR (KBr) 3300 cm'", 3050 ( , 52.79; H, 7.80; N, 9.85. Found: C, 52.55; H, 7.71; N, 10.17 . 18 and 19) The 3'-ketonuc1eoside 14 (0.3 g, 0.6 mmol) was treated with NaCN (0.029 g, 0.6 mmol), NaHC0 3 (0.101 g, 1.2 mmol) and then with CSI (0.078 mL; 0.9 mmol) following the procedure described for the synthesis of compounds 6 and 7. Then, methylene chloride (30 mL) and water (30 mL) were added. The reaction mixture was stirred at room temperature for 1 h. After the workup, the residue was purified by CCTLC on the chromatotron (hexane: ethyl acetate, 2 : 1). The fastest moving 510 band gave compound 19 (0.017 g, 6%) as a white foam. IR (KBr) 3400 cm'", 3300 (NH 2), 2200 (CN), 1740, 1710, 1670 (C=O). Anal. calcd for C2sH44N407Si2: C, 52.79; H, 7.80; N, 9.85. Found: C, 52.50; H, 7.43; N, 9.98 .
The slowest moving band gave 0.074 g (22%) of 18 as a white foam. IR (KBr) 3400 cm'", 3300 (NH 2), 2200 (CN), 1740, 1690, 1625 (C=O). Anal. calcd for C2sH44NP7Si2: C, 52.79; H, 7.80; N, 9.85. Found: C, 53.09; H, 8.11; N, 9.45 . [1] [2] '-spiro-5"-(4"amino-1",2",3"-oxathiazole-2",2"-dioxide) and [1-[2',5'-bis-O-(tert-butyldimethylsilyl) -f3-D-ribofuranosyl]-3-N-methylthymine]-3' -spiro-5"-(4"amino-1",2",3"-oxathiazole-2",2"-dioxide) (20 and 21) Compound 14 (1 g, 2 mmol) was reacted with NaCN (0.098 g, 2 mmol) and NaHC0 3 (0.336 g, 4 mmol) as described for the synthesis of 6 and 7. The mixture of the two epimeric cyanohydrins (15 and 16) was dissolved in dry dioxane (20 mL), and then sulphamoyl chloride (0.92 g,8 mmol) and DMAP/Py (up to approximately pH 8) were added. The reaction mixture was stirred at room temperature for 5 days. The solvent was evaporated to dryness and the residue was purified by column chromatography (hexane: ethyl acetate, 3: 1). The fastest moving fractions afforded compound 20 (0.484 g, 40%) as an amorphous solid. IR (KBr) 1680 ern"! (C=C-N), 1360, 1180 (S02)' 13C NMR (CDC1 3, 50 MHz) [) 13.49 (CH 3-5), 17.95, 18.14 (C-Si), 25.71 [(CH3kC-Si], 28.09 (CH 3-3), 59.05 (C-5'), 82.33, 82.78 (C-2', C-4'), 91.53, 92.48 (C-1', C-3'), 111.38 (C-5), 132.65 (C-6), 151.11 (C-2), 163.23, 165.73 (C-4, C-4"). Anal. calcd for C24H44N40gSSi2: C, 47.66; H, 7.33; N, 9.26; S, 5.30. Found: C, 47.93; H, 7.25; N, 9.21; S, 5.55 .
The slowestmovingfractions gavecompound 21 (0.097 g, 8%) as an amorphous solid.IR (KBr) 1680 ern"! (C=C-N), 1370,1185 (S02)' 13C NMR (CDCl 3, 50 MHz) 0 12.89 (CH 3-5), 17.92, 18.37 (C-Si), 25.26, 25.92 [(CH 3 )3-C-Si], 28.10 (CH 3-3), 61.51 (C-5'), 74.95, 82.79 (C-2', C-4'), 91.44, 93.46 (C-1', C-3'), 111.48 (C-5), 135.74 (C-6),151.08 (C-2), 162.90, 166.78 (C-4, C-4"). Anal. calcd for C24H44N40gSSi2: C, 47.66; H, 7.33; N, 9.26; S, 5.30. Found: C, 47.82; H, 7.10; N, 9.40; S, 5.46. 
Materials and Experimental Procedures: Virology
Cells and viruses CEM cellswere obtained from the ATCC (Rockville, Md., USA). MT-4 cells were a kind gift ofN Yamamoto 
Antiviral assays
The anti-HIV-1 and -HIV-2 acnvity of the test compounds was examined in CEM cells at day 4 and in MT-4 cells at day 5 post-infection. Determination of antiviral activity was based on giant cell formation in CEM cells and cell viability (trypan blue dye staining) in MT-4 cells. HIV-1 or HIV-2 was added at approximately 100 CCID so (50% cell culture infective dose) to the cell cultures. Briefly, CEM and MT-4 cells were suspended at aound 300 000 cells ml.? of RPMI 1640 culture medium and infected with HIV-1 u IB or HIV-2 ROD ' Then, 100 ilL of the infected cell suspension was added to 200 ilL microtitre plate wells containing 100 ul, of an appropriate dilution of the test compounds. After4 days (CEM cells) or 5 days (MT-4 cells) of incubation at 3TC, the cell cultures were examined for syncytium formation and cell viability, respectively. The 50% effective concentration (EC so ) was determined as the compound concentration required to inhibit by 50% syncytium formation or cell lysis in HIV-infected CEM or MT-4 cells, respectively. The 50% cytotoxic concentration (CC so ) was determined as the compound concentration required to reduce the cell viability of mock-infected MT-4 cells by 50% or to inhibit CEM cell proliferation by 50%.
Results

Chemistry
Our strategy for the synthesis of this new series of 3'-spiro nucleosideswas based on the functionalization and closureof the corresponding cyanohydrins (xylo and ribo) obtained from 3'-ketonucleosides. This strategy allowed us to obtain in two-three steps highly functionalized nucleosidesstarting from a common precursor.The nucleosides bearing a spiro oxazolone moiety at the 3' position (6 and 7) were prepared by reaction of cyanohydrins, obtained from 3'-ketonucleosides, with cWorosulphonylisocyanate (CSI) to give, after basic treatment, the target 3'-spiro nucleosides.Thus, reaction of3'-ketonuc1eoside 3 (Calvo-Mateo et al., 1988a) (Fig.  2) with sodium cyanide, in a two phase ethyl ether: water system, in the presence of sodium bicarbonate, gave a mixture of the two epimeric nucleoside 3'-cyanohydrins 4 and 5 Calvo-Mateo et al., 1988a) . These cyanohydrins were used in the next step without further purification. Reaction of the cyanohydrin mixture (4 and 5) with CSI, followedby treatment with saturated aqueous NaHC0 3 gave a 4.5: 1 mixture ofthe xylo and ribo spiro nucleosides6 and 7 at 66% overallyield. Owing to the insolubility of the compounds from the reaction mixture after successive purifications only the major compound, the xylo isomer 6, could be obtained in a pure state. In order to increase the solubility of the spironucleosides (6 and 7) and facilitate the separation of both isomers, they were alkylated at the N-3 of the thymine base following the method used for the selective N-3-alkylation ofTSAO derivatives . However, treatment of the mixture of spironucleosides 6 and 7 with methyl iodide in the presence of~C03 afforded a complex reaction mixture from which only xyio compounds methylated at the base moiety (8) and at both the base and the 3'-spiro moieties (9 and 10) could be isolated in very low yields. Compounds 9 and 10 were obtained in 30% and 52% yield, respectively, when spironucleoside 8 was treated with methyl iodide in the presence of C03'
The absolute configuration of C-3' and the imine configuration in 9 and 10 were unequivocally determined by NOESY experiments. Thus, the correlation peaks observed between H-4' and NH-4" in compound 9 and between H-4' and H-1' and NCH 3-4" in 10, indicated a xyio configuration of the furanose ring and an E stereochemistry of the imine in both compounds.
Owing to the difficulty in obtaining the desired ribospiro nucleosides in a pure form, a new synthetic strategy was devised which allowed us to methylate the N-3 of the thymine base in a step previous to the formation of the 3'spiro ring. Spironucleosides obtained by this new strategy had the base moiety of the most selective TSAO compound (TSAO-m 3T, 2) obtained by alkylation ofN-3 of thymine ofTSAO-T; this alkylation markedly reduced cytotoxicity without affecting the antiviral activity . of potassium carbonate to give the N-3 methyl derivative 12 in 84% yield (Fig. 3) . Deprotection of 12 with saturated methanolic ammonia followed by reaction with tert-butyldimethylsilyl chloride afforded the 2' ,5'-bis-O-silylated nucleoside 13 in 55% yield. Oxidation of 13 with CrO/pyridine/Ac 20 (Hansske et al., 1984) gave the 3'ketonucleoside 14 in 82% yield. Reaction of 14 with sodium cyanide in the presence of sodium bicarbonate afforded a mixture of the two epimeric 3'-cyanohydrins 15 and 16 (Hansske et al., 1984) . These cyanohydrins on standing in solution reversed to the corresponding ketonucleoside 14. Thus, they were not isolated and were used without further purification in the next step. Reaction of the cyanohydrin mixture (15 and 16) with chlorosulphonyl isocyanate (Sarges et al., 1982; Garcia et al., 1991) (Fig. 4 ) followed by treatment with saturated aqueous NaHC0 3 solution gave the respective 3'-spiro xylo-and ribo-furanosyl nucleosides 8 (43%) and 17 (9%). However, when the reaction was carried out using water instead of aqueous NaHC0 3 in the hydrolysis step, the carbamates 18 (22%) and 19 (6%) were obtained. Finally, Fig. 4 outlines the preparation of 3'-spiro oxathiazole dioxide nucleosides 20 and 21. In these compounds, the spiro ring was constructed by reaction of cyanohydrins with sulphamoyl chloride. Thus, reaction of the cyanohydrin mixture (15 and 16) with sulphamoyl chloride in the presence of DMAP afforded the 3'-spiro derivatives 20 (40%) and 21 (8%).
The structures of the new spiro compounds were assigned on the basis of the corresponding analytical and spectroscopic data ( Table 1) . The spiro moieties at the 3'-position of compounds 8, 17, 20 and 21 could exist in different tautomeric forms (Fig. 5) . The spectroscopic data were compatible with both tautomer I and II but not tautomer III. The predominant tautomer (in acetone) for compounds 8, 17,20 and 21 was unequivocally determined by heteronuclear inverse detection lH-15N (HMQC) NMR experiments ). An HMQC experiment carried out on compound 17 indicated that the proton of the spiro moiety appearing at 7.83 p.p.m. was directly bonded to a nitrogen which appeared shielded 294 p.p.m. with respect to nitromethane (reference signal). A similar experiment carried out with compound 21 showed that the protons at 7.92 p.p.m. and 8.39 p.p.m. were directly bonded to a nitrogen shielded 295 p.p.m. with respect to nitromethane. These results were only compatible with an enamine type structure (Hayakawa et al., 1987) and therefore with tautomer II, in both compounds. These results are in agreement with literature data for enamine-type I$"ogens (as in tautomer II), whose signals appear shielded around 300 p.p.m. (Witanowsky et al., 1993) with respect to nitromethane. Imine-type nitrogens (as in tautomers I and III), on the other hand, appear shielded around 190-200 p.p.m. (Witanowsky et al., 1993) . A lH-15N HMBC experiment on compound 21, which correlates long distance coupled proton and nitrogen atoms , allowed us to assign the endocyc1ic nitrogen atom. Thus, a correlation signal was observed between the proton at 7.92 p.p.m. and an sp2 nitrogen (166.4 p.p.m.), which confirmed the proposed structure for compound 21. 514 The absolute configuration at C-3' for nucleosides 8, 17-21 was assumed to be the same as that of the corresponding starting cyanohydrins 15 and 16 and were assigned as xylo for the major compounds (8, 18 and 20) and ribo for the minor compounds (17, 19 and 21) . The stereochemical assignments are in agreement with the relative steric hindrance of the upper (P) or lower (a) sides of the furanose ring. As clearly demonstrated in previous papers of this series (Perez-Perez ssal., 1991 Calvo-Mateo et al., 1988b) , the xylo configuration of the major compounds 8, 18 and 20 resulted from the approach of the CN-ion to the ulose 14 from the stericallyless hindered a face of the furanose ring, opposite to the base and the 5'-O-substituent. This is in agreement with the stereochemistry observed by our group (Perez-Perez et al., 1991 Calvo-Mateo et al., 1988b) and other laboratories (Hayakawa et al., 1987) for reaction of nucleoside uloses with NaCN and other nucleophiles (RLi, RMgBr and Al) (Hayakawa et al., 1987) . The assignment.s of spironuc1eosides 8 and 20 as xylo and 17 and 21 as rihowere confirmed by NOESY experiments carried out on the corresponding spiro derivatives 17 and 21. These compounds showed correlation peaks between the NH-4" proton and the H-2' and H-5' protons, which are compatible with a ribo configuration.
Antiviral activity
The TSAO derivatives 6, 8-10 and 17-21 were evaluated for their inhibitory effect on HIV-1-and HIV-2-induced giant cell formation in CEM and cytopathicity in MT-4 cell cultures. None of the test compounds were inhibitory to HIV-2 replication. Also, the 4 1-amino-2"-oxazolonep-n-xylofuranosyl analogues of TSAO-T (6) and TSAO-m 3T (8) and the 4"-imino-3"-N-methyl-2"oxazolidinone (9) and 4"-N-methylimino-3"-N-methyl-2"-oxazolidinone (10)~-D-xylofuranosyl analogues of TSAO-m 3T were devoid of antiviral activity (Table 2) .
Interestingly, moderate antiviral activity, although around 100-fold less pronounced than that observed for the parent TSAO-m 3T derivative, was observed for 17 (EC so 5.8-13 I-tM), although this compound was somewhat more cytotoxic than TSAO-m 3T (CC so 44 I-tM). Also, the ribo compound 21, but not its corresponding~ D-xylofuranosyl derivative 20, showed antiviral activity (EC so 5.3 !-tM), but also a markedly enhanced cytotoxicity compared with TSAO-m 3T rcc., 5.2-16 !-tM). In general, -D-ribofuranosyl nucleosides showed a higher cytotoxicity profile than the corresponding~-D-xylofuranosyl derivatives (Table 2 ). Finally, the 3'-O-carbamoyl-3'-C-cyano~ D-ribo-(19) and~-D-xylo-(18) furanosyl analogues were devoid of antiviral efficacyat subtoxic concentrations.
Discussion
TSAO-T should be considered as the first nucleoside analogue that selectively inhibits HIV-l replication. In this respect it behaves like the non-nucleoside reverse transcriptase inhibitors (TIBO, HEPT, a-APA, etc.) that all bind at a non-substrate binding site.
To the best of our knowledge, compounds 6, 8-10, 17, 20 and 21 represent the very first examples of spiro nucleosides bearing a 4-amino-2-oxazolone or a 4-amino-1,2,3-oxathiazole-2,2-dioxide moiety at the 3'-position of the sugar residue. The newly developed synthetic procedures to prepare these novel 3'-spiro nucleosides were based on the functionalization and closure of the corresponding xy/o and ribo cyanohydrin derivatives of 3'ketonucleosides. Although it has been almost a general rule that TSAO derivatives in the xy/o configuration are devoid of anti-HIV-l activity, it was surprising to note that the ribo derivatives containing a 4"-amino-2"oxazolone (17) and 4" -amino-L",2" ,3"-oxathiazole-2",2"-dioxide (21) spiro moiety at the 3'-position of the ribose ring were endowed with an anti-HIV-l activity that was at least two orders of magnitude lower than their corresponding 3'-spiro-4"-amino-l",2"-oxathiole-2" ,2"dioxide derivatives (TSAO). The markedly decreased potency of 17 and 21 against HIV-1 replication is in agreement with their decreased anti-HIV-1 reverse transcriptase activity. These observations point again to a highly specific interaction of the 3'-spiro moiety of TSAO-T with the RT that is of crucial importance to retain antiviral activity.Our data confirm the spiro-oxathioledioxide moiety ofTSAO-T as being the essential pharmacophore of the molecule and stress how subtle structural differences at the 3'-spiro moiety of TSAO Antiviral Chemistry & Chemotherapy 8 (6) 3' Spiro nucleoside analoguesof TSA0-T compounds may have a major impact on the eventual antiviral activity of the test compounds.
Studies are currently ongoing in our laboratory to determine the factors that may help to understand the markedly decreased potency of TSAO analogues 17 and 21. These include both a comparative experimental conformational study by NMR spectroscopy between TSAO-T and these analogues, as well as a comparison of the basicity of the amino group of the spiro moieties in the three compounds and other physico-chemical properties.
